Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 20/20 | 0.63 |
| ▸ | PROKR2 | Q8NFJ6 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058307 | 0.89 | PROKR1 (0.68) | PROKR1PROKR2 | |
| SCHEMBL1752302 | 0.87 | PROKR1 (0.61) | PROKR1PROKR2 | |
| SCHEMBL5054615 | 0.83 | PROKR1 (0.64) | PROKR1PROKR2 | |
| SCHEMBL2027078 | 0.83 | PROKR1 (0.62) | PROKR1PROKR2 | |
| SCHEMBL5960121 | 0.81 | PROKR1 (0.73) | PROKR1PROKR2 | |
| SCHEMBL326449 | 0.81 | PROKR1 (0.82) | PROKR1PROKR2 | |
| SCHEMBL1751295 | 0.80 | PROKR1 (0.60) | PROKR1PROKR2 | |
| SCHEMBL1751296 | 0.78 | PROKR1 (0.66) | PROKR1PROKR2 | |
| SCHEMBL8520244 | 0.77 | PROKR1 (0.65) | PROKR1PROKR2 | |
| SCHEMBL1750898 | 0.76 | PROKR1 (0.59) | PROKR1PROKR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20110136811-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R | 2011-06-09 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | PROKR1 2/4885PROKR2 1/4885 |
| US-20110136811-A1 | PROKINETICIN 1 RECEPTOR | PROKR1, PROKR2, GIPR | PROKR1 1/4885PROKR2 2/4885 |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | PROKR1, PROKR2, GIPR | PROKR1 1/4885PROKR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.